A study of Baricitinib in children and young adults with JIA associated eye inflammation
An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis - JUVE-BRIGHT An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Y ...